The Latest
This Week in HIV Research: When STIs Flock Together
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Large Scale HIV Vaccine Trial Announced, But PrEP May Challenge Enrollment
Will potential study participants choose a vaccine trial over getting access to PrEP?
IAS 2019: What to Expect in HIV Science
Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Government Panel Finds PrEP Is Effective, Must Be Available Free of Cost to Patients
The US Preventive Services Task Force released its final ruling in *JAMA*.
New Campaign, Toolkit Gets Providers PrEP'd for Women
New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.
New Website Helps People Trying to Navigate Their PrEP Options
A team led by Shannon Weber, M.S.W., has developed PleasePrEPMe, an online PrEP provider search and chat service.
Primary Care Providers Aware of PrEP in NYC Suburbs, but Report Barriers to Prescribing
Anthony J. Santella, Dr.P.H., explains why prevention efforts are lagging within the largest suburban HIV epidemic in the U.S.
This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
This Week in HIV Research: Fentanyl Smooths the Path for HIV
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Many Providers Are Biased Against Prescribing PrEP to People Who Inject Drugs
Health care providers often believe stereotypes that PWID are irresponsible and won't adhere to PrEP, according to data presented at the 2019 National HIV Prevention Conference.